» Articles » PMID: 37425061

The Feasibility of Oral Targeted Drug Delivery: Gut Immune to Particulates?

Overview
Publisher Elsevier
Specialty Pharmacology
Date 2023 Jul 10
PMID 37425061
Authors
Affiliations
Soon will be listed here.
Abstract

Targeted drug delivery is constantly updated with a better understanding of the physiological and pathological features of various diseases. Depending on high safety, good compliance and many other undeniable advantages, attempts have been undertaken to complete an intravenous-to-oral conversion of targeted drug delivery. However, oral delivery of particulates to systemic circulation is highly challenging due to the biochemical aggressivity and immune exclusion in the gut that restrain absorption and access to the bloodstream. Little is known about the feasibility of targeted drug delivery oral administration (oral targeting) to a remote site beyond the gastrointestinal tract. To this end, this review proactively contributes to a special dissection on the feasibility of oral targeting. We discussed the theoretical basis of oral targeting, the biological barriers of absorption, the fate and transport mechanisms of drug vehicles, and the effect of structural evolution of vehicles on oral targeting as well. At last, a feasibility analysis on oral targeting was performed based on the integration of currently available information. The innate defense of intestinal epithelium does not allow influx of more particulates into the peripheral blood through enterocytes. Therefore, limited evidence and lacking exact quantification of systemically exposed particles fail to support much success with oral targeting. Nevertheless, the lymphatic pathway may serve as a potentially alternative portal of peroral particles into the remote target sites M-cell uptake.

Citing Articles

Nanometerizing Taxifolin Into Selenized Liposomes to Ameliorate Its Hypoglycemic Effect by Optimizing Drug Release and Bioavailability.

Qi C, Xing H, Ding N, Feng W, Wu Y, Zhang X Int J Nanomedicine. 2025; 20:2225-2240.

PMID: 40007903 PMC: 11853828. DOI: 10.2147/IJN.S510378.


Recent Advances in Propranolol Hydrochloride Formulations for the Treatment of Infantile Hemangiomas.

Ren L, Xu X, Liu X, Ning H, Ding Q, Yang M Drug Des Devel Ther. 2025; 19:1163-1183.

PMID: 39991089 PMC: 11846487. DOI: 10.2147/DDDT.S496847.


Solubilization techniques used for poorly water-soluble drugs.

Xie B, Liu Y, Li X, Yang P, He W Acta Pharm Sin B. 2024; 14(11):4683-4716.

PMID: 39664427 PMC: 11628819. DOI: 10.1016/j.apsb.2024.08.027.


Enteral Route Nanomedicine for Cancer Therapy.

Zhang L, Du R, Wang D, Qin J, Yu C, Zhang L Int J Nanomedicine. 2024; 19:9889-9919.

PMID: 39351000 PMC: 11439897. DOI: 10.2147/IJN.S482329.


Fabrication of Luteolin Nanoemulsion by Box-Behnken Design to Enhance its Oral Absorption Via Lymphatic Transport.

Tu L, Wang J, Sun Y, Wan Y AAPS PharmSciTech. 2024; 25(7):206.

PMID: 39237659 DOI: 10.1208/s12249-024-02898-4.


References
1.
Date A, Hanes J, Ensign L . Nanoparticles for oral delivery: Design, evaluation and state-of-the-art. J Control Release. 2016; 240:504-526. PMC: 5064878. DOI: 10.1016/j.jconrel.2016.06.016. View

2.
Ren T, Gou J, Sun W, Tao X, Tan X, Wang P . Entrapping of Nanoparticles in Yeast Cell Wall Microparticles for Macrophage-Targeted Oral Delivery of Cabazitaxel. Mol Pharm. 2018; 15(7):2870-2882. DOI: 10.1021/acs.molpharmaceut.8b00357. View

3.
Das R, Gandhi V, Singh B, Kunwar A . Passive and Active Drug Targeting: Role of Nanocarriers in Rational Design of Anticancer Formulations. Curr Pharm Des. 2019; 25(28):3034-3056. DOI: 10.2174/1381612825666190830155319. View

4.
Zhong X, Chen B, Yang Z . Nanocochleates as the Potential Delivery Systems for Oral Antitumor of Hydroxycamptothecin. J Biomed Nanotechnol. 2018; 14(7):1339-1346. DOI: 10.1166/jbn.2018.2572. View

5.
Yang D, Liu D, Qin M, Chen B, Song S, Dai W . Intestinal Mucin Induces More Endocytosis but Less Transcytosis of Nanoparticles across Enterocytes by Triggering Nanoclustering and Strengthening the Retrograde Pathway. ACS Appl Mater Interfaces. 2018; 10(14):11443-11456. DOI: 10.1021/acsami.7b19153. View